Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
Quanterix (QTRX) announces a new partnership path for laboratories interested in offering Tau-based research and diagnostic testing services. The company has secured over 30 U.S. patents, including one directed specifically to measuring Tau protein levels in biologic samples. Quanterix is focused on expanding clinical access to its leading blood biomarker assays in light of FDA approval of an Alzheimer's disease therapy.
The announcement by Quanterix Corporation regarding their partnership path for laboratories to offer Tau based research and diagnostic testing services signifies a strategic move to monetize their intellectual property. With over thirty U.S. patents, Quanterix is reinforcing its position in the competitive landscape of ultra-sensitive research products and diagnostics. Their focus on Tau protein, a biomarker for Alzheimer's disease, is timely given the aging population and the increasing prevalence of neurodegenerative diseases.
From a business perspective, the ability to offer non-exclusive licenses to their patented technology potentially opens up new revenue streams. This is particularly significant as it allows for broader adoption of their Tau protein measurement techniques without diluting their market position. Moreover, the threat of infringement litigation against parties using other platforms for Tau measurement could act as a deterrent, pushing more laboratories towards Quanterix's licensed technology.
The healthcare industry is closely watching the development of diagnostic tools for Alzheimer's disease, especially with the FDA's approval of new AD therapies. Quanterix's emphasis on building global infrastructure for AD testing speaks to the market demand for accessible and reliable blood biomarker assays. The company's established collaborations with health system entities suggest a focused strategy to integrate their products into clinical practice.
Investors should note the potential for growth in this sector, as early and accurate diagnosis of AD can lead to better disease management and improved patient outcomes. Quanterix's position in this market, backed by a strong patent portfolio, presents an opportunity for the company to capitalize on the expanding need for diagnostic services in neurology.
Intellectual property protection is a cornerstone for innovation in the biotech industry. Quanterix's portfolio of patents, particularly U.S. Patent No. 11,275,092, provides them with a legal framework to control the use of their novel Tau protein measurement technique. This control is important for maintaining a competitive edge and justifies their significant investment in research and development over the past decade.
The announcement of potential partnership opportunities and the warning against infringement highlight Quanterix's proactive approach to intellectual property management. By offering licensing options, Quanterix not only safeguards their technology but also encourages its adoption, balancing exclusivity with market penetration. The implications for stakeholders include a clear legal pathway for utilizing Quanterix's technology and the assurance of support from a company with a robust legal standing.
03/21/2024 - 05:30 PM
BILLERICA, Mass. --(BUSINESS WIRE)--
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in the United States and abroad. Multiple patents—including U.S. Patent No. 11,275,092—are directed specifically to our novel approach to measuring Tau protein levels in biologic samples.
Those interested in building Alzheimer’s disease (AD) testing infrastructure should contact Quanterix to discuss potential partnership opportunities, including avenues for receiving a non-exclusive license to U.S. Patent No. 11,275,092, to measure Tau protein using Quanterix’s novel technique. As previously announced , Quanterix has already established collaborations with multiple health system entities to offer its instruments and assay tests to aid in the diagnosis and clinical management of individuals with AD. Those parties are thus already enjoying the benefits of Quanterix’s novel Tau measuring techniques. Parties currently measuring Tau protein in relation to a neurological condition in a research or diagnostic setting on any other platform risk infringement of Quanterix’s intellectual property.
For over 10 years, Quanterix has invested significant resources in the development of ultra-sensitive assay tests and enhancing research and diagnostics through improved accessibility to blood biomarker tests. We take this investment and efforts to invent and innovate seriously. With the advent of FDA approval of an AD therapy, Quanterix is focused on building the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays. Licensing inquiries can be directed to licensing@quanterix.com .
In conjunction with this announcement, the Company will host a conference call on March 25, 2024 at 4:00 p.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at http://www.quanterix.com .
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,700 peer-reviewed journals. Find additional information about the Billerica, Massachusetts -based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321224578/en/
Media:
pan.quanterix@pancomm.com
Investor Relations:
ir@quanterix.com
Source: Quanterix
How many U.S. patents has Quanterix secured?
Quanterix has secured over thirty U.S. patents.
What is the specific focus of the U.S. Patent No. 11,275,092 held by Quanterix?
The U.S. Patent No. 11,275,092 held by Quanterix is specifically directed to measuring Tau protein levels in biologic samples.
What is Quanterix's main goal following the FDA approval of an Alzheimer's disease therapy?
Following the FDA approval of an Alzheimer's disease therapy, Quanterix is focused on building the global infrastructure necessary for AD testing by expanding clinical access to its leading blood biomarker assays.
How can laboratories interested in offering Tau-based research and diagnostic testing services partner with Quanterix?
Laboratories interested in offering Tau-based research and diagnostic testing services can contact Quanterix to discuss potential partnership opportunities, including avenues for receiving a non-exclusive license to U.S. Patent No. 11,275,092.
